Puma Biotechnology - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsPuma Biotechnology

Puma Biotechnology(PBYI)

Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Nerlynx	Neratinib	2017-07-17	2025-2031	Breast neoplasms

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

healthy volunteers/patients

,

myelodysplastic syndromes

,

myeloid leukemia acute

,

hematologic neoplasms

,

myeloproliferative disorders

,

non-hodgkin lymphoma

,

primary myelofibrosis

,

multiple myeloma

,

precursor cell lymphoblastic leukemia-lymphoma

,

b-cell chronic lymphocytic leukemia

,

bcr-abl positive chronic myelogenous leukemia

,

myelomonocytic leukemia chronic

,

,

hodgkin disease

,

leukemia myeloid chronic atypical bcr-abl negative

,

myelodysplastic-myeloproliferative diseases

,

myeloid leukemia chronic-phase

,

myeloid leukemia accelerated phase

,

,

,

,

,

,

hepatic insufficiency

,

gastrointestinal neoplasms

,

esophageal squamous cell carcinoma

,

,

neoplasm metastasis

,

triple negative breast neoplasms

,

brain neoplasms

,

stomach neoplasms

,

pancreatic neoplasms

,

non-small-cell lung carcinoma

,

,

prostatic neoplasms

,

castration-resistant prostatic neoplasms

,

,

colorectal neoplasms

,

,

ovarian neoplasms

,

inflammatory breast neoplasms

,

neurofibromatosis 2

,

acoustic neuroma

,

,

,

hemangiosarcoma

,

pathologic complete response

,

hereditary sensory and autonomic neuropathies

,

colonic neoplasms

,

disease progression

,

,

,

,

central nervous system neoplasms

,

,

endometrial neoplasms

,

fallopian tube neoplasms

,

lobular carcinoma

,

invasive hydatidiform mole

,

,

pancreatic ductal carcinoma

,

,

,

adenosquamous carcinoma

,

breast neoplasms

,

,

biliary tract neoplasms

,

uterine cervical neoplasms

,

urinary bladder neoplasms

,

neoadjuvant therapy

pancreatic ductal carcinoma

,

pancreatic neoplasms

,

,

acinar cell carcinoma

,

myeloid leukemia acute

healthy volunteers/patients

,

ovarian neoplasms

,

triple negative breast neoplasms

,

non-small-cell lung carcinoma

,

castration-resistant prostatic neoplasms

,

,

colorectal neoplasms

,

lobular carcinoma

,

fallopian tube neoplasms

,

ovarian epithelial carcinoma

,

,

type 2 diabetes mellitus

,

prostatic neoplasms

,

endocrine system diseases

,

diabetes mellitus

,

male breast neoplasms

,

,

unilateral breast neoplasms

,

,

glucose metabolism disorders

,

metabolic diseases

,

,

,

nutrition disorders

,

signs and symptoms

,

nutritional and metabolic diseases

,

signs and symptoms pathological conditions

,

,

neoplasm metastasis

,

breast neoplasms

,

,

,

pituitary dwarfism

,

left ventricular hypertrophy

,

left ventricular dysfunction

,

bipolar disorder

,

coronary disease

,

coronary artery disease

,

chronic disease

,

traumatic brain injuries

,

brain concussion

,

hypopituitarism

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use